WuXi Biologics Wins CDMO of the Year

SHANGHAI, Oct.
14, 2022 /PRNewswire/ -- WuXi Biologics (2269.
HK), a leading global contract research, development and manufacturing (CRDMO) services company, announced its 2022 Asia-Pacific Biologics CMO Excellence at IMAPAC Awards, APBCEA) won the "CDMO of the Year"
award.
Since 2017, WuXi Biologics has won several awards at IMAPAC
.

APBCEA recognizes CMOs or CDMOs in the field of biopharmaceutical contract manufacturing that have made outstanding contributions to accelerating biopharmaceutical R&D, reducing costs and improving quality, and the 2022 award is determined
by the voting results of more than 200 biopharmaceutical companies or industry service companies in the Asia-Pacific region.
WuXi Biologics received the highest number of votes in this category and was awarded the "CDMO of the Year" honor.

Dr.
Zhisheng Chen, CEO of WuXi Biologics, said, "We are honored to be recognized
once again for the IMAPAC Awards.
The 'CDMO of the Year' award represents the trust and confidence
of our customers.
As a trusted CRDMO partner and enabler for the biopharmaceutical industry, WuXi Biologics is committed to providing end-to-end biopharmaceutical solutions
.
We will continue to accelerate and transform the global biologics discovery, development and manufacturing process to empower our global partners for the benefit of patients
.
" "

About WuXi Biologics

WuXi Biologics (stock code: 2269.
HK) is a leading global contract research, development and production (CRDMO) company
.
Through an open, integrated biopharmaceutical capability and technology enablement platform, the company provides a full range of end-to-end services to help partners discover, develop and produce biopharmaceuticals, realize the whole process from concept to commercial production, accelerate the global biopharmaceutical R&D process, reduce R&D costs, and benefit patients
.

WuXi Biologics has more than 10,000 employees
in China, the United States, Ireland, Germany and Singapore.
With a professional services team of these employees, as well as superior technology and insight, the company provides customers with efficient and cost-effective biopharmaceutical solutions
.
As of the end of June 2022, WuXi Biologics has helped customers develop and manufacture 534 integrated projects, including 14 commercial manufacturing projects
.

WuXi Biologics regards environmental, social and governance (ESG) as an important part of business development and entrepreneurial spirit, and is committed to becoming an ESG leader in the global biopharmaceutical CRDMO, such as leading the industry in
the application of greener, next-generation biopharmaceutical technologies and energy.
The company has established an ESG committee led by the CEO to fully implement its ESG strategy and commitment to
sustainability.

For more information, please visit: www.
wuxibiologics.
com
.